UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
|
|
| (Exact name of registrant as specified in its charter) |
|
|
|
| ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
|
| |||
| (Address of principal executive offices) (Zip Code) | |||
| Registrant’s
telephone number, including area code ( | |||
|
| |||
| (Former name or former address, if changed since last report) | |||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule l2b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.02 | Results of Operations and Financial Condition. |
The following information is being provided pursuant to Item 2.02. Such information, including Exhibit 99.1 attached hereto, should not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
On May 10, 2021, Intricon Corporation (the “Company”) announced earnings for the quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
| Item 7.01 | Regulation FD Disclosure. |
The following information is being provided pursuant to Item 7.01. Such information, including Exhibit 99.1 attached hereto, should not be deemed “filed” for purposes of Section 18 of the Exchange Act.
The information contained under Item 2.02 is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. | |
| (d) | Exhibits |
| Exhibit No. | Description | ||
| 99.1 | Press Release dated May 10, 2021. | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INTRICON CORPORATION | |||||
| Date: May 10, 2021 | By: |
/s/ Scott Longval | |||
| Scott Longval | |||||
| President and
Chief Executive Officer (principal executive officer) |
|||||
| Date: May 10, 2021 | By: |
/s/ Ellen Scipta | |||
| Ellen Scipta | |||||
| Chief Financial Officer (principal financial officer) | |||||
INTRICON REPORTS FIRST QUARTER 2021 RESULTS
ARDEN HILLS, Minn. — May 10, 2021 — Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its first quarter ended March 31, 2021.
First Quarter Highlights:
| • | Revenue of $31.8 million increased $10.3 million compared to $21.5 million in the prior year period | |
| • | Gross margin of 25.8%, compared to 21.3% in the prior year period | |
| • | GAAP net income of $0.7 million or $0.07 per diluted share versus net loss of $2.0 million or $0.22 per diluted share in the prior year period | |
| • | Non-GAAP adjusted net income of $2.5 million or $0.26 per diluted share in the first quarter of 2021, versus a net loss of $0.7 million or $0.08 per diluted share, for the 2020 first quarter | |
| • | As of March 31, 2021, the company had $38.3 million of cash and investment securities, compared to $33.5 million as of December 31, 2020 | |
| • | Appointed Kathleen Pepski to Board of Directors | |
“Our first quarter results illustrate a strong start to the year despite some ongoing pandemic related headwinds. Encouragingly, we saw meaningful year-over-year improvement throughout our business driven by pent up demand from Medtronic’s diabetes business and strong Hearing Health revenues in our legacy OEM business. In addition, Emerald Medical Services (EMS) continued to grow at a pace that exceeded our initial expectations, contributing $3.8 million to our topline in the first quarter,” said Scott Longval, President and Chief Executive Officer.
“As we enter the second quarter, there remains lingering impacts from COVID-19, including staffing challenges coupled with input supply constraints primarily associated with the February Texas storms. I am confident that with our constant focus on strong execution we will overcome these short-term challenges to deliver solid year over year growth,” Longval concluded.
First Quarter 2021 Financial Results
Revenue
Net revenue for the fiscal year 2021 first quarter increased 48% to $31.8 million versus $21.5 million in the comparable prior-year period.
Revenue in Intricon’s Medical business increased 54% to $25.1 million from $16.4 million in the comparable prior-year period. The year-over-year increase was driven primarily by higher diabetes revenues from increased demand for products as COVID-19 restrictions eased as well as the impact of EMS, which the company acquired in May 2020.
Hearing Health revenue increased 46% to $5.7 million in the first quarter of 2021 compared to $3.9 million in the prior-year quarter. The primary growth driver in this market was our legacy hearing health business, which continued to benefit from increased access to audiologists as restrictions were lifted. We also saw revenue contributions in our Indirect to End Consumer market, related to volumes required to support an initial OTC pilot.
(more)
Gross Margin and Operating Expenses
Gross margin in the first quarter of 2021 was 25.8%, compared to 21.3% in the prior-year first quarter, primarily due to higher volumes and product mix.
Operating expenses for the first quarter were $7.4 million, compared to $6.6 million in the comparable prior-year period. The increase was due to $0.9 million of expenses associated with higher wages, salaries, incentives, and stock-based compensation expense, $0.6 million in EMS operating expenses, and $0.4 million of additional amortization expense of certain intangible assets, partially offset by a $1.1 million reduction in Hearing Help Express operating expenses due to the second quarter 2020 restructuring.
GAAP Net Income
The company posted GAAP net income of $0.7 million or $0.07 per diluted share in the first quarter of 2021, versus a net loss of $2.0 million or $0.22 per diluted share, for the 2020 first quarter.
Non-GAAP Income
The company posted non-GAAP adjusted net income of $2.5 million or $0.26 per diluted share in the first quarter of 2021, versus a net loss of $0.7 million or $0.08 per diluted share, for the 2020 first quarter. See “Reconciliation of Adjusted Net Income and Earnings Per Share” in the tables that follow.
Guidance
Intricon expects full year 2021 revenue to range between $119 million and $123 million, representing year-over-year growth of 16-20%. We do not anticipate providing regular quarterly guidance. However, we do expect our second quarter revenue to slightly lag our first quarter results due to COVID-19 related pent up demand recognized in the first quarter of 2021 and present challenges regarding staffing and input supply constraints.
Conference Call
Intricon will hold a conference call today, May 10, 2021, beginning at 4:00 p.m. CT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 866-795-7248 for domestic callers or 470-495-9160 for international callers, using conference ID: 9769435. A live and archived webcast will be available on the “Investors” sections of the company’s website at: www.Intricon.com.
Use of non-GAAP Adjusted Financial Measures
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:
| · | Adjusted net income |
| · | Adjusted net income per diluted share |
These non-GAAP financial measures reflect adjustments for expenses and gains that the company believes do not reflect the company’s core operating performance. We have presented these non-GAAP financial measures because we believe this presentation, when reconciled to the corresponding GAAP measures, provides useful information to investors in evaluating the company’s operational performance. Management uses these non-GAAP measures internally to evaluate our performance and in making financial, operational and planning decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results and trends. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in comparing the company’s financial results with the financial results of other companies.
The company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.
Non-GAAP financial measures should not be used as a substitute for GAAP measures, or considered in isolation, for the purpose of analyzing our operating performance. The presentation of these non-GAAP financial measures should not be construed as an inference that future results will not be affected by similar items.
Forward-Looking Statements
Statements made in this release and in Intricon’s other public filings and releases that are not historical facts or
that include forward-looking terminology, including estimates of future results, are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be affected by known
and unknown risks, uncertainties and other factors that are beyond Intricon’s control, including without limitation, the
impacts of the COVID-19 pandemic and measures taken in response, and may cause Intricon’s actual results, performance or
achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements.
These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities
and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2020. The company disclaims any
intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes
available, future developments occur or otherwise.
About Intricon Corporation
Intricon is a Joint Development Manufacturer that integrates components and assemblies to advance micro-medical technology across
a range of device platforms for global customers. Intricon approaches each engagement with an all-in commitment, working with customers
every step of the way- from the earliest idea stages to ongoing production - in order to advance program performance and deliver
results. With a focus on key device platforms, Intricon helps advance clinical outcomes by always looking ahead with proactive
support and resources through integration of its core competencies. Intricon has facilities in the United States, Asia and Europe.
The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market.
| Investor Contact |
| Leigh Salvo |
| (415) 937-5404 |
| investorrelations@intricon.com |
INTRICON CORPORATION
MARKET REVENUE
(Unaudited)
| FIRST QUARTER | ||||||||
| ($ in 000’s) | 2021 | 2020 | Change | |||||
| Diabetes | $ | 18,364 | 13,530 | 35.7% | ||||
| Interventional Catheters | 3,802 | — | 100.0% | |||||
| Other Medical | 2,958 | 2,828 | 4.6% | |||||
| Hearing Health Value Based DTEC | 937 | 1,173 | -20.1% | |||||
| Hearing Health Value Based ITEC | 1,301 | 744 | -74.9% | |||||
| Hearing Health Legacy OEM | 3,421 | 1,964 | 74.2% | |||||
| Professional Audio Communications | 985 | 1,264 | -22.1% | |||||
| Total | $ | 31,768 | $ | 21,503 | 47.7% | |||
INTRICON CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)
| Three Months Ended | ||||||||
| (unaudited) | March 31, | March 31, | ||||||
| 2021 | 2020 | |||||||
| Revenue, net | $ | 31,768 | $ | 21,503 | ||||
| Cost of goods sold | 23,558 | 16,931 | ||||||
| Gross profit | 8,210 | 4,572 | ||||||
| Operating expenses: | ||||||||
| Sales and marketing | 1,982 | 1,993 | ||||||
| General and administrative | 4,052 | 3,416 | ||||||
| Research and development | 1,293 | 1,201 | ||||||
| Other operating expenses | 35 | — | ||||||
| Total operating expenses | 7,362 | 6,610 | ||||||
| Operating income (loss) | 848 | (2,038 | ) | |||||
| Interest (expense) income, net | (9 | ) | 184 | |||||
| Other expense, net | (77 | ) | (107 | ) | ||||
| Income (loss) before income taxes | 762 | (1,961 | ) | |||||
| Income tax expense | 90 | 18 | ||||||
| Net income (loss) | 672 | (1,979 | ) | |||||
| Less: Loss allocated to non-controlling interest | (42 | ) | — | |||||
| Net income (loss) attributable to Intricon shareholders | $ | 714 | $ | (1,979 | ) | |||
| Income (loss) per share attributable to Intricon shareholders: | ||||||||
| Basic | $ | 0.08 | $ | (0.22 | ) | |||
| Diluted | 0.07 | (0.22 | ) | |||||
| Average shares outstanding: | ||||||||
| Basic | 8,994 | 8,813 | ||||||
| Diluted | 9,607 | 8,813 | ||||||
INTRICON CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEET
(In Thousands, Except Per Share Amounts)
| (unaudited) | March 31, | December 31, | ||||||
| 2021 | 2020 | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,757 | $ | 8,608 | ||||
| Restricted cash | 654 | 672 | ||||||
| Short-term investment securities | 23,699 | 19,793 | ||||||
| Accounts receivable, net of $152 and $210 of reserves, respectively | 9,452 | 10,115 | ||||||
| Inventories | 20,336 | 19,513 | ||||||
| Contract assets | 8,787 | 9,107 | ||||||
| Other current assets | 1,956 | 1,466 | ||||||
| Total current assets | 76,641 | 69,274 | ||||||
| Property, plant and equipment | 46,480 | 45,661 | ||||||
| Less: Accumulated depreciation | 32,319 | 31,484 | ||||||
| Net property, plant and equipment | 14,161 | 14,177 | ||||||
| Goodwill | 13,804 | 13,714 | ||||||
| Intangible assets | 10,288 | 10,785 | ||||||
| Operating lease right-of-use assets, net | 6,115 | 6,701 | ||||||
| Investment in partnerships | 600 | 570 | ||||||
| Long-term investment securities | 2,765 | 5,085 | ||||||
| Other assets, net | 876 | 990 | ||||||
| Total assets | $ | 125,250 | $ | 121,296 | ||||
| Current liabilities: | ||||||||
| Current financing leases | $ | 12 | $ | 21 | ||||
| Current operating leases | 2,108 | 2,156 | ||||||
| Accounts payable | 12,132 | 8,670 | ||||||
| Accrued salaries, wages and commissions | 3,915 | 3,581 | ||||||
| Other accrued liabilities | 4,297 | 4,235 | ||||||
| Total current liabilities | 22,464 | 18,663 | ||||||
| Noncurrent operating leases | 4,166 | 4,726 | ||||||
| Other postretirement benefit obligations | 374 | 385 | ||||||
| Accrued pension liabilities | 834 | 907 | ||||||
| Deferred tax liabilities, net | 1,028 | 1,018 | ||||||
| Other long-term liabilities | 4,139 | 4,398 | ||||||
| Total liabilities | 33,005 | 30,097 | ||||||
| Commitments and contingencies (Note 11) | ||||||||
| Shareholders’ equity: | ||||||||
| Common stock, $1.00 par value per share; 20,000 shares authorized; 8,999 and 8,951 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively | 8,999 | 8,951 | ||||||
| Additional paid-in capital | 89,926 | 89,702 | ||||||
| Accumulated deficit | (6,096 | ) | (6,810 | ) | ||||
| Accumulated other comprehensive loss | (527 | ) | (679 | ) | ||||
| Total shareholders’ equity | 92,302 | 91,164 | ||||||
| Non-controlling interest | (57 | ) | 35 | |||||
| Total equity | 92,245 | 91,199 | ||||||
| Total liabilities and equity | $ | 125,250 | $ | 121,296 | ||||
INTRICON CORPORATION
Reconciliation of Adjusted Net Income and Earnings Per Share
(Unaudited)
| Three Months Ended | ||||||||
| ($ in 000's) | March 31, | March 31, | ||||||
| 2021 | 2020 | |||||||
| Net income - GAAP attributable to Intricon | $ | 714 | $ | (1,979 | ) | |||
| Identified adjustments attributable to Intricon: | ||||||||
| Depreciation (1) | 841 | 686 | ||||||
| Amortization of intangibles (2) | 497 | 98 | ||||||
| Stock-based compensation (3) | 453 | 376 | ||||||
| Other amortization (4) | 102 | 137 | ||||||
| EMS acquisition costs (5) | 35 | — | ||||||
| COVID-19 Singapore government support (6) | (121 | ) | — | |||||
| Non-GAAP adjusted net income attributable to Intricon (7) | $ | 2,521 | $ | (682 | ) | |||
| Non-GAAP adjusted net income attributable to Intricon per diluted share | $ | 0.26 | $ | (0.08 | ) | |||
(1) Depreciation represents the expense of property, plant and equipment.
(2) These expenses represent amortization expenses of intangible assets.
(3) Stock-based compensation represents expenses related to awards under the Company's equity incentive plans.
(4) These expenses represent amortization of other assets..
(5) These expenses represent changes in the fair value of contingent consideration in the period for the purchase of EMS..
(6) The Singapore Government provided $121 in COVID-19 financial assistance to our Singapore subsidiaries during the period.
(7) None of these adjustments have material income tax impacts.
Cover |
May 10, 2021 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | May 10, 2021 |
| Entity File Number | 1-5005 |
| Entity Registrant Name | INTRICON CORPORATION |
| Entity Central Index Key | 0000088790 |
| Entity Tax Identification Number | 23-1069060 |
| Entity Incorporation State Country Code | PA |
| Entity Address, Address Line One | 1260 Red Fox Road |
| Entity Address, City or Town | Arden Hills |
| Entity Address, State or Province | MN |
| Entity Address, Postal Zip Code | 55112 |
| City Area Code | 651 |
| Local Phone Number | 636-9770 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, par value $1.00 per share |
| Trading Symbol | IIN |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Entity Information Former Legal Or Registered Name | N/A |
R#\WS'A^W6^&OQWS^X>P%YXX!$X* (,PA^O)0@G:E'C<$\5DXF]
M["M !$Z,@>PO,-E[%+X"ZG